Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Pliant Therapeutics to post earnings of ($0.37) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02). On average, analysts expect Pliant Therapeutics to post ($1.42) EPS for the current fiscal year and ($1.53) EPS for the next fiscal year.
Pliant Therapeutics Price Performance
PLRX stock opened at $0.86 on Wednesday. The firm has a fifty day moving average price of $1.03 and a 200 day moving average price of $1.16. Pliant Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $1.81.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on PLRX shares. Wall Street Zen raised shares of Pliant Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pliant Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.00.
View Our Latest Report on PLRX
Pliant Therapeutics Company Profile
Pliant Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. The company’s research is centered on integrin biology, a field involving proteins that regulate cell communication and tissue remodeling. Pliant aims to develop medicines that address the underlying processes that drive fibrosis in organs such as the lungs and liver.
Pliant’s lead investigational product is bexotegrast, an oral, selective inhibitor of the integrins αvβ1 and αvβ6.
Read More
- Five stocks we like better than Pliant Therapeutics
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
